<DOC>
	<DOCNO>NCT01290120</DOCNO>
	<brief_summary>The study set assess efficacy tolerability chemotherapy-immunotherapy combination programme originally introduce GMALL ( German cooperative group adult acute lymphoblastic leukemia ) 2002 , improve remission rate , overall disease-free survival rate adult patient Burkitt 's leukemia lymphoma . The therapy include maximum six chemotherapy course ( two high dos methotrexate cytarabine ) plus anti-CD20 antibody ( Rituximab , 8 total dos ) , supplement local radiation therapy case initial mediastinal central nervous system ( CNS ) involvement residual tumor chemotherapy .</brief_summary>
	<brief_title>Chemotherapy Plus Rituximab Combination Adult Lymphoblastic Leukemia ( B-ALL ) Burkitt 's Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>Cycle A1 : prednisone-cyclophosphamide pre-phase ( 5 day ) , Rituximab day 0 , chemotherapy day 1-5 ( dexamethasone , iphosphamide , vincristine , high-dose methotrexate , triple intrathecal therapy ) . Cycle B1 : Rituximab day 0 , chemotherapy day 1-5 ( dexamethasone , vincristine , cyclophosphamide , high-dose methotrexate , adriamycin , triple intrathecal therapy ) Cycle C1 : Rituximab day 0 , chemotherapy day 1-5 ( dexamethasone , vindesine , high-dose methotrexate , etoposide , high-dose cytarabine ) . Cycle A2 : like cycle A1 , without pre-phase . Cycle B2 : like cycle B1 . Cycle C2 : like cycle C1 . Cycle C2 follow two additional Rituximab injection . Notes : 1. patient stage I-II disease without mediastinal tumor extranodal involvement receive first 4 cycle ( A1 A2 ) . 2. patient age &gt; 55 year receive cycle C ( sequence : A1 , B1 , A2 , B2 , A3 , B3 A1 , B1 , A2 , B2 limit stage , reduced-dose methotrexate ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Burkitt 's leukemia lymphoma ( new diagnosis ) Written informed consent Age &gt; 15 year pretreated Burkitt 's leukemia lymphoma psychiatric disorder active second malignancy pregnancy absence patient 's write informed consent participation study interfere study therapy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>B-ALL</keyword>
	<keyword>Adult patient</keyword>
</DOC>